Furuse K, Fukuoka M, Genka K, Kato H, Tsubura E, Ohta M, Nakai H, Kinuwaki E, Nakano M, Ishikawa S
National Kinki Central Hospital.
Gan To Kagaku Ryoho. 1993 Jul;20(9):1187-94.
To investigate effects of the combination of ubenimex, chemotherapy, and radiotherapy against unresectable advanced squamous cell carcinoma of the lung, a placebo controlled double-blind study was performed. Of 365 registered cases, there were 258 cases in the complete radiation group in which the treatment as specified in the protocol (irradiation of 40 Gy or more to the thorax subsequent to chemotherapy) was conducted; the 50% survival time was 449 days and 363 days in the ubenimex group and the placebo group, respectively. A significant (p = 0.0473) prolongation of the survival time was noted in the ubenimex group, and the response rate was 60.9% and 50.0% (p = 0.087). From these results it was confirmed that ubenimex, when used in combination with chemotherapy and radiotherapy, not only enhances the tumor-reducing effect but also prolongs the survival time.
为研究乌苯美司联合化疗及放疗对不可切除的晚期肺鳞状细胞癌的疗效，开展了一项安慰剂对照双盲研究。在365例登记病例中，有258例在完全放疗组，按照方案进行了规定治疗（化疗后对胸部照射40 Gy或以上）；乌苯美司组和安慰剂组的50%生存时间分别为449天和363天。乌苯美司组的生存时间有显著延长（p = 0.0473），缓解率分别为60.9%和50.0%（p = 0.087）。从这些结果证实，乌苯美司与化疗和放疗联合使用时，不仅增强了肿瘤缩小效果，还延长了生存时间。
